We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-18.45%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$122M
AUM Growth
+$7.43M
Cap. Flow
+$13.4M
Cap. Flow %
10.99%
Top 10 Hldgs %
82.45%
Holding
116
New
28
Increased
22
Reduced
30
Closed
27

Top Buys

Rank Stock Value
1
BCLI
BRAINSTORM CELL THERAPUTC
BCLI
+$3.5M
2
PBLA
Panbela Therapeutics, Inc. Common Stock
PBLA
+$2.24M
3
SIDU icon
Sidus Space
SIDU
+$1.75M
4
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
+$1.7M
5
GCTK icon
GlucoTrack
GCTK
+$1.22M

Top Sells

Rank Stock Value
1
APCX
AppTech Payments
APCX
+$1.03M
2
CNEY icon
CN Energy Group
CNEY
+$799K
3
ARDS
Aridis Pharmaceuticals Inc. Common Stock
ARDS
+$672K
4
DOGZ icon
Dogness International Corp
DOGZ
+$543K
5
HUDI icon
Huadi International Group
HUDI
+$528K

Sector Composition

Rank Sector Weight
1 Healthcare 14.59%
2 Consumer Discretionary 2%
3 Industrials 1.44%
4 Financials 1.38%
5 Communication Services 1.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PULM icon
26
Pulmatrix
PULM
$6.14M
$493K 0.4%
184,074
-35,955
-16% -$101K
CNTN
27
Canton Strategic Holdings
CNTN
$157M
$483K 0.4%
+3,534
New +$710K
BETS
28
DELISTED
Bit Brother Limited Class A Ordinary Shares
BETS
$479K 0.39%
911
+175
+24% +$139K
HCDI
29
DELISTED
Harbor Custom Development, Inc. Common Stock
HCDI
$466K 0.38%
+154,143
New +$664K
RKDA icon
30
Arcadia Biosciences
RKDA
$1.37M
$459K 0.38%
118,213
+65,339
+124% +$348K
PHIO icon
31
Phio Pharmaceuticals
PHIO
$11.7M
$450K 0.37%
+17,417
New +$612K
RNAZ icon
32
TransCode Therapeutics
RNAZ
$5.29M
$433K 0.35%
+5
New +$977K
GMDA
33
PUT
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$433K 0.35%
+2,244
New +$3.86K
VRPX
34
DELISTED
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
$432K 0.35%
1,600
-1,206
-43% -$250K
NCPL icon
35
Netcapital
NCPL
$2.97M
$422K 0.35%
5,447
+5,111
+1,521% +$481K
GLBS icon
36
Globus Maritime Ltd
GLBS
$60.9M
$370K 0.3%
411,907
-18,839
-4% -$18.4K
LFWD icon
37
ReWalk Robotics
LFWD
$19.6M
$340K 0.28%
6,755
+773
+13% +$40.3K
NRXP icon
38
NRX Pharmaceuticals
NRXP
$152M
$338K 0.28%
+69,973
New +$421K
BBIO icon
39
CALL
BridgeBio Pharma
BBIO
$16.8B
$334K 0.27%
194
– –
REVB icon
40
Revelation Biosciences
REVB
$4.06M
$332K 0.27%
61
+30
+97% +$188K
SCNI
41
Scinai Immunotherapeutics
SCNI
$1.36M
$269K 0.22%
19,093
-13,504
-41% -$233K
ADTX
42
DELISTED
ADITXT INC
ADTX
– –
0
– –
GMVD
43
DELISTED
G Medical Innovations Holdings Ltd. Ordinary Shares
GMVD
$263K 0.21%
690,334
-659,666
-49% -$297K
MOBQ
44
DELISTED
Mobiquity Technologies, Inc. Common Stock
MOBQ
$248K 0.2%
144,485
+69,697
+93% +$180K
IMPP icon
45
PUT
Imperial Petroleum
IMPP
$212M
$245K 0.2%
+795
New +$2.65K
NEPT
46
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$237K 0.19%
40,390
+30,349
+302% +$433K
WLDSW icon
47
Wearable Devices Ltd Warrant
WLDSW
$135K
$230K 0.19%
1,599
-2,102
-57% -$282K
KPRX icon
48
Kiora Pharmaceuticals
KPRX
$11.4M
$201K 0.16%
+34,708
New +$727K
SVRN
49
OceanPal Inc
SVRN
$11.7M
$195K 0.16%
238
+142
+148% +$316K
SMFL
50
DELISTED
Smart for Life, Inc. Common Stock
SMFL
$192K 0.16%
3,958
+3,864
+4,111% +$719K
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2023 Portfolio in Review

As of Q2 2023, Sabby Management held 116 positions worth $122M, up 6.5% from $115M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Sabby Management deployed $13.4M of net new capital in Q2 2023, opening 28 new positions and adding to 22 existing holdings. Its largest new stake was BRAINSTORM CELL THERAPUTC: 84,525 shares worth $2.61M.

By sector, the portfolio is most concentrated in Healthcare at 15% of assets, up from 9.8% a quarter earlier, followed by Consumer Discretionary and Industrials.

On the sell side, the largest reduction was CN Energy Group, an estimated $799K trimmed.

  • Sabby Management's largest Q2 2023 buy was BRAINSTORM CELL THERAPUTC: 84,525 shares worth $2.61M.
  • Sabby Management added most to Panbela Therapeutics, Inc. Common Stock in Q2 2023, an estimated $2.24M increase.
  • Sabby Management's biggest Q2 2023 reduction was CN Energy Group, cutting an estimated $799K.
  • Sabby Management fully exited AppTech Payments in Q2 2023, selling an estimated $1.03M.
  • Sabby Management's ten largest holdings make up 82% of its $122M portfolio in Q2 2023.
  • Sabby Management opened 28 new positions and closed 27 in Q2 2023.
  • Sabby Management's portfolio value rose 6.5% quarter-over-quarter to $122M.

Based on Sabby Management's 13F filing for Q2 2023, filed 14 Aug 2023.